Lamotrigine Tablet
NDC Package 69918-370-30
Package Information
Lamotrigine tablets is lamotrigine is used alone or with other medications to prevent and control seizures. This formulation utilizes a tablet delivery system. Marketed by Nordic Pharma, Inc., this product is identified by NDC 69918-370 and is authorized under FDA application ANDA214124.
Identification & Billing
- RxCUI: 103968 - lamoTRIgine 100 MG Disintegrating Oral Tablet
- RxCUI: 103968 - lamotrigine 100 MG Disintegrating Oral Tablet
- RxCUI: 198430 - lamoTRIgine 25 MG Disintegrating Oral Tablet
- RxCUI: 198430 - lamotrigine 25 MG Disintegrating Oral Tablet
- RxCUI: 252478 - lamoTRIgine 50 MG Disintegrating Oral Tablet
Clinical Specifications
- Anti-epileptic Agent - [EPC] (Established Pharmacologic Class)
- Decreased Central Nervous System Disorganized Electrical Activity - [PE] (Physiologic Effect)
- Dihydrofolate Reductase Inhibitors - [MoA] (Mechanism of Action)
- Mood Stabilizer - [EPC] (Established Pharmacologic Class)
- Organic Cation Transporter 2 Inhibitors - [MoA] (Mechanism of Action)
Regulatory & Marketing
Hierarchy Structure
- 69918 - Nordic Pharma, Inc.
- 69918-370 - Lamotrigine
- 69918-370-30 - 30 TABLET in 1 BOTTLE
- 69918-370 - Lamotrigine
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 69918-370-30 identifies a specific commercial package of 30 tablet in 1 bottle of Lamotrigine, a human prescription drug labeled by Nordic Pharma, Inc.. This tablet is formulated for oral use and contains lamotrigine as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Nordic Pharma, Inc. on February 14, 2022. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
Lamotrigine is used alone or with other medications to prevent and control seizures. It may also be used to help prevent the extreme mood swings of bipolar disorder in adults. Lamotrigine is known as an anticonvulsant or antiepileptic drug. It is thought to work by restoring the balance of certain natural substances in the brain. This drug is not approved for use in children younger than 2 years due to an increased risk of side effects (such as infections).
How is this Nordic Pharma, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 69918037030. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.